Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

0(0%)

Results Posted

67%(2 trials)

Phase Distribution

Ph phase_2

33%

Ph phase_4

33%

Ph not_applicable

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 4Post-market surveillance

1(33.3%)

N/ANon-phased studies

1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 4

Trials by Phase

Phase 21 (33.3%)

Phase 41 (33.3%)

N/A1 (33.3%)

Trials by Status

completed3100%

Recent Activity

0 active trials

Showing 3 of 3

completedphase_4

Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients

NCT00421473

completednot_applicable

Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2

NCT03454048

completedphase_2

Weekly Dosing of Malarone ® for Prevention of Malaria

NCT00984256

Clinical Trials (3)

Showing 3 of 3 trials

NCT00421473Phase 4

Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients

Completed

NCT03454048Not Applicable

Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2

Completed

NCT00984256Phase 2

Weekly Dosing of Malarone ® for Prevention of Malaria

Completed

All 3 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 3